NCT01295840

Brief Summary

The purpose of this Clinical Trial is to determine the percentage of patients whose hemodynamic response improves with the different configurations offered by the new Quartet® left ventricular lead, as a result of its four electrodes, with respect to the configurations offered by a standard bipolar lead. Furthermore, the optimal stimulation configuration will be determined from a comparison with traditional configurations.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
51

participants targeted

Target at P25-P50 for phase_4 heart-failure

Timeline
Completed

Started Jan 2011

Shorter than P25 for phase_4 heart-failure

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2011

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

February 3, 2011

Completed
12 days until next milestone

First Posted

Study publicly available on registry

February 15, 2011

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2012

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2012

Completed
2.5 years until next milestone

Results Posted

Study results publicly available

March 6, 2015

Completed
Last Updated

February 20, 2019

Status Verified

February 1, 2019

Enrollment Period

1.2 years

First QC Date

February 3, 2011

Results QC Date

June 6, 2014

Last Update Submit

February 1, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Patients Whose Cardiac Output (CO) Value in Acute, as Measured Echocardiographically, Improves With the Different Stimulation Vectors Offered by the Quartet® Left Ventricular Electrode.

    Enrollment visit (in the seven days after implantation of the device)

Secondary Outcomes (10)

  • Percent Difference Between the Best CO From Non-traditional Vectors and Best CO From Traditional Vectors

    At enrollment

  • Cardiac Output (CO) With Different Configurations at Enrollment

    Enrollment visit (in the seven days after implantation of the device)

  • Capture Threshold

    Enrollment visit (in the seven days after implantation of the device)

  • Capture Threshold

    6 months post-implant

  • Number of Vectors With Phrenic Nerve Stimulation (PNS)

    Enrollment visit (in the seven days after implantation of the device)

  • +5 more secondary outcomes

Study Arms (1)

CRT therapy

NO INTERVENTION

Cardiac Resynchronization Therapy Defibrillator (CRT-D)

Device: Cardiac Resynchronization Therapy Defibrillator

Interventions

Cardiac Resynchronization Therapy Defibrillator

Also known as: Promote Q. Model, Promote Quadra™., Quartet®: Tetrapolar left ventricular lead. Model 1458Q.
CRT therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with a Cardiac resynchronization Therapy Defibrillator device (CRT-D) and a Quartet® quadripolar electrode from St Jude Medical (used in "Single Site Pacing" mode) implanted in the left ventricle.
  • Patients who have provided written informed consent
  • Patients who are in sinus rhythm.
  • Patients older than 18 years of age.

You may not qualify if:

  • Patients in atrial fibrillation at the time of the echocardiographic study of the enrollment visit.
  • Patients with valvular disease.
  • Patients in functional class New York Heart Association (NYHA) IV
  • Patients for whom echocardiography images suitable for determining the cardiac output cannot be obtained.
  • Patients whose device has been changed/upgraded.
  • Pregnant patients.
  • Patients who are unable to provide written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Clínico Universitario Virgen de la Victoria

Málaga, 29010, Spain

Location

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Results Point of Contact

Title
Dr Javier Alzueta
Organization
Hospital Universitario Virgen de la Victoria

Study Officials

  • Dr. Francisco Javier Alzueta Rodríguez, PhD

    Hospital Clínico Universitario Virgen de la Victoria

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 3, 2011

First Posted

February 15, 2011

Study Start

January 1, 2011

Primary Completion

April 1, 2012

Study Completion

September 1, 2012

Last Updated

February 20, 2019

Results First Posted

March 6, 2015

Record last verified: 2019-02

Locations